Solid Tumor, Adult Clinical Trials

93 recruiting

Solid Tumor, Adult Trials at a Glance

94 actively recruiting trials for solid tumor, adult are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 1 with 68 trials, with the heaviest enrollment activity in New York, Houston, and Nashville. Lead sponsors running solid tumor, adult studies include Second Affiliated Hospital of Guangzhou Medical University, Memorial Sloan Kettering Cancer Center, and A2 Biotherapeutics Inc..

Browse solid tumor, adult trials by phase

Treatments under study

About Solid Tumor, Adult Clinical Trials

Looking for clinical trials for Solid Tumor, Adult? There are currently 93 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Tumor, Adult trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Tumor, Adult clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 94 trials

Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Solid Tumor, Adult
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1Phase 2

GT201 Injection For The Treatment Of Advanced Solid Tumors

Solid Tumor, Adult
Grit Biotechnology18 enrolled4 locationsNCT06144671
Recruiting
Phase 1Phase 2

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Solid Tumor, Adult
Virginia Commonwealth University83 enrolled1 locationNCT03919292
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1Phase 2

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Solid Tumor, Adult
BioInvent International AB197 enrolled25 locationsNCT04219254
Recruiting
Phase 1Phase 2

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics US, Inc.375 enrolled21 locationsNCT03686124
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Solid Tumor, AdultGastrointestinal Stromal Tumor (GIST)
Ascentage Pharma Group Inc.100 enrolled6 locationsNCT03594422
Recruiting
Phase 1

A Study of VET3-TGI in Patients With Solid Tumors

Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+10 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting
Phase 1Phase 2

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

NSCLCSolid Tumor, AdultMesothelioma
Vivace Therapeutics, Inc434 enrolled12 locationsNCT04665206
Recruiting
Phase 1Phase 2

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

Solid Tumor, Adult
DualityBio Inc.360 enrolled36 locationsNCT06554795
Recruiting
Not Applicable

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

Solid Tumor, Adult
Centre Oscar Lambret651 enrolled1 locationNCT05223608
Recruiting
Phase 1Phase 2

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

Solid Tumor, AdultProstate Cancer Recurrent
Medical University of South Carolina76 enrolled1 locationNCT05036226
Recruiting
Phase 1

First In Human Study of CX-2051 in Advanced Solid Tumors

Solid Tumor, Adult
CytomX Therapeutics160 enrolled5 locationsNCT06265688
Recruiting
Phase 1Phase 2

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

Solid Tumor, Adult
Accession Therapeutics Limited72 enrolled7 locationsNCT06977737
Recruiting
Phase 1

First In Human Study of CX-801 in Advanced Solid Tumors

Solid Tumor, Adult
CytomX Therapeutics121 enrolled2 locationsNCT06462794
Recruiting

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Solid Tumor, AdultHealthy DonorsCOVID-19 Donors
BioCytics, Inc.1,500 enrolled1 locationNCT00571389
Recruiting
Phase 1Phase 2

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Solid Tumor, Adult
Akeso87 enrolled1 locationNCT05689853
Recruiting
Phase 1Phase 2

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771